These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25749875)

  • 1. The role of checkpoints in the treatment of GBM.
    Kim JE; Lim M
    J Neurooncol; 2015 Jul; 123(3):413-23. PubMed ID: 25749875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
    Mirzaei R; Sarkar S; Yong VW
    Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intersection between genetic engineering and immunotherapy: taking a BiTE out of glioblastoma.
    Njoku I; Boockvar JA
    Neurosurgery; 2013 Jun; 72(6):N16-7. PubMed ID: 23685511
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
    Luksik AS; Maxwell R; Garzon-Muvdi T; Lim M
    Neurotherapeutics; 2017 Oct; 14(4):1049-1065. PubMed ID: 28258545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
    Samaha H; El Naggar S; Ahmed N
    Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
    [No Abstract]   [Full Text] [Related]  

  • 14. New perspectives in glioma immunotherapy.
    Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
    Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 17. [Brain tumor immunotherapy: Illusion or hope?].
    Migliorini D; Dutoit V; Walker PR; Dietrich PY
    Bull Cancer; 2017 May; 104(5):476-484. PubMed ID: 28318492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and Immunotherapeutic Targets in Glioblastoma.
    Hung AL; Garzon-Muvdi T; Lim M
    World Neurosurg; 2017 Jun; 102():494-506. PubMed ID: 28300714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
    Bagley SJ; Hwang WT; Brem S; Linette GP; O'Rourke DM; Desai AS
    J Neurooncol; 2019 Jan; 141(1):95-102. PubMed ID: 30353265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.